The approval was based on the Phase III CASPIAN trial, in which the risk of death was reduced by 27%.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.